1	Viability RT-PCR for SARS-CoV-2: a step forward to solve the infectivity quandary
2	
3	Enric Cuevas-Ferrando, MSc ¹ ; Walter Randazzo, PhD ¹ ; Alba Pérez-Cataluña, PhD ¹ ; Irene
4	Falcó, MSc ¹ ; David Navarro, PhD ^{2,3} ; Sandra Martin-Latin, PhD ⁴ ; Azahara Díaz-Reolid,
5	MSc ¹ ; Inés Girón-Guzmán, BSc ¹ ; Ana Allende, PhD ⁵ ; Gloria Sánchez, PhD ^{1*}
6	
7	¹ Department of Preservation and Food Safety Technologies, Institute of Agrochemistry
8	and Food Technology, IATA-CSIC, Av. Agustín Escardino 7, Paterna, 46980, Valencia,
9	Spain
10	² Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
11	Valencia, Spain
12	³ Department of Microbiology, School of Medicine, University of Valencia, Valencia,
13	Spain
14	⁴ Université Paris-Est, ANSES Laboratory for Food Safety, Maisons-Alfort, F-94700, France
15	⁵ Research Group on Quality and Safety of Fruits and Vegetables, Department of Food
16	Science and Technology, CEBAS-CSIC, Campus Universitario de Espinardo, 25, 30100,
17	Murcia, Spain
18	
19	*Corresponding author
20	Correspondence to: gloriasanchez@iata.csic.es

21 Summary

22 Background: Isolation, contact tracing and restrictions on social movement are being globally 23 implemented to prevent and control onward spread of SARS-CoV-2, even though the infection 24 risk modelled on RNA detection by RT-qPCR remains biased as viral shedding and infectivity are 25 not discerned. Thus, we aimed to develop a rapid viability RT-qPCR procedure to infer SARS-CoV-26 2 infectivity in clinical specimens and environmental samples. Methods: We screened 27 monoazide dyes and platinum compounds as viability molecular markers on five SARS-CoV-2 28 RNA targets. A platinum chloride-based viability RT-qPCR was then optimized using genomic 29 RNA, and inactivated SARS-CoV-2 particles inoculated in buffer, stool, and urine. Our results 30 were finally validated in nasopharyngeal swabs from persons who tested positive for COVID-19 31 and in wastewater samples positive for SARS-CoV-2 RNA. Findings: We established a rapid 32 viability RT-qPCR that selectively detects potentially infectious SARS-CoV-2 particles in complex 33 matrices. In particular, the confirmed positivity of nasopharyngeal swabs following the viability 34 procedure suggests their potential infectivity, while the complete prevention of amplification in 35 wastewater indicated either non-infectious particles or free RNA. Interpretation: The viability 36 RT-qPCR approach provides a more accurate ascertainment of the infectious viruses detection 37 and it may complement analyses to foster risk-based investigations for the prevention and 38 control of new or re-occurring outbreaks with a broad application spectrum. Fundings: This work 39 was supported by Spanish Scientific Research Council (CSIC), Generalitat Valenciana, and 40 MICINN co-founded by AEI/FEDER, UE.

41 Introduction

42 The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to 43 an unprecedented global health and economic crisis. SARS-CoV-2 belongs to the Coronaviridae 44 family, which includes enveloped RNA viruses causing respiratory, enteric, and systemic 45 infections in a wide range of hosts, including humans and animals. Human coronaviruses have 46 been traditionally considered responsible for endemic infections causing common cold 47 symptoms, as in the cases of HKU1, 229E, OC43, and NL63 viruses, while more recently Middle 48 East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV produced more severe 49 epidemics in the Arabian Peninsula and in Asia. COVID-19 symptoms range from mild to severe, 50 in which severe pneumonia and respiratory distress syndrome can lead to death. However, a 51 significant number of infected people are asymptomatic, making the epidemiological control 52 even more challenging.

53 SARS-CoV-2 is an airborne human pathogen primarily transmitted through droplets and 54 aerosols, even though its detection in urine and faecal specimens raised the hypothesis of the 55 possible fecal-oral transmission further sustained by the successful viral replication in cell 56 culture.^(1,2) To control SARS-CoV-2 spread, extreme containment measures have been enforced 57 worldwide along with several epidemiological surveillance strategies, which include tracing 58 confirmed and suspected cases by clinical testing (e.g., SARS-CoV-2 nucleic acid or antigen tests 59 on nasal or oral swabs or saliva samples), and monitoring community transmission by 60 wastewater analysis (known as Wastewater Based Epidemiology, WBE).⁽³⁾

61 In this context, several molecular assays based on real-time reverse transcriptase polymerase 62 chain reaction (RT-qPCR) have been developed to detect and quantify SARS-CoV-2 RNA in clinical 63 and environmental samples. For instance, a test-based strategy (at least two consecutive 64 negative RT-qPCR tests) has been widely adopted as a general public health guidance for release 65 from (self-) isolation, reincorporation into the workplace, and patient transferral. However, 66 COVID-19 patients can continue to shed viral RNA well beyond clinical recovery and persistent 67 positive RT-qPCR does not necessarily indicate infectiousness.⁽⁴⁾ Besides being a rapid, easy-touse, and cost-effective technique, RT-qPCR informs on the presence of viral RNA that does not 68 69 correlate with infectivity, yet such testing is still being used as a surrogate marker of infectivity. $^{(5-)}$ 70 ⁸⁾ On the contrary, viral replication in permissive cell line(s) represents the conclusive evidence 71 to assess viral infectivity, and it has been readily available for SARS-CoV-2. Conversely, the facility 72 requirements needed to handle SARS-CoV-2 infectious materials (biosafety level 3 laboratory, 73 BSL-3), in addition to the low sensitivity and long turnaround time for results, typically from 74 three to ten days, limited its extensive implementation for both clinical diagnosis and 75 environmental risk assessment.⁽⁹⁾

Recently, novel molecular techniques, referred to as capsid integrity or viability qPCR assays incorporating viability markers such as monoazide dyes and metal compounds into qPCR-based methods, have been demonstrated to selectively remove false-positive qPCR signals deriving from free nucleic acids and virions with damaged capsids, finally allowing an estimation on viral infectivity.⁽¹⁰⁾ However, the application of such techniques for enveloped viruses has not fully elucidated as it has failed for avian influenza virus (IAV) and infectious laryngotracheitis virus (ILTV) while it has recently been optimized for porcine epidemic diarrhea coronavirus.^(11–13)

83 Nonetheless, the implementation of this technique has not been explored for SARS-CoV-2.

84 Methods

85 Viral materials, viability markers and optimization of viability treatment

86 SARS-CoV-2 genomic RNA (VR-1986D[™], ATCC, VA, US), gamma-irradiated (5 × 10⁶ RADs)

87 (NRC-52287, BEI Resources, VA, US) and heat inactivated (65°C for 30 min) (NR-52286, BEI

88 Resources, VA, US) viral particles preparations all obtained from isolate USA-WA1/2020 were

89 used for initial screening of viability markers. Specifically, monoazide photoactivatable dyes and

90 platinum compounds were initially screened as viability marker candidates using SARS-CoV-2

- 91 genomic RNA, gamma-inactivated, and heat inactivated SARS-CoV-2 suspensions. Viability
- 92 marker stock solutions were prepared as follows and stored at -20 °C for later use: ethidium

93 monoazide (EMA™, Geniul, Spain) was diluted in dimethylsulfoxide (DMSO) to 2.0 mM, PEMAX™ 94 (Geniul, Spain) and propidium monoazide (PMAxx™, Biotium, CA, US) were diluted in nuclease-95 free water to 4.0 mM, platinum (IV) chloride (PtCl4; Acros Organics, NJ, US) and cis-96 diamineplatinum (II) dichloride (CDDP; Sigma-Aldrich, MO, US) salts were dissolved in DMSO to 97 1.0 M and further diluted in nuclease-free water to 50 mM. Viability assays were carried out by 98 treating 300 μ L of either genomic SARS-CoV-2 RNA (approx. 10³ gc/mL), gamma-inactivated 99 (approx. 10⁵ gc/mL), and heat inactivated SARS-CoV-2 (approx. 10⁵ gc/mL) suspensions with final 100 concentrations of 50-100 µM photoactivatable dyes (PMAxx[™], PEMAX[™], or EMA[™]) or 0·1-2·0 101 mM platinum compounds (CDDP or PtCl₄) in DNA LoBind tubes (Eppendorf, Germany). 102 Photoactivation of monoazide dyes was achieved by 10 min of dark-incubation in an orbital 103 shaker (150 rpm) at room temperature (RT) followed by 15 min blue LED light exposure in a 104 photo-activation system (Led-Active Blue, GenIUL). Alternatively, 30 min incubation at RT in an 105 orbital shaker (150 rpm) were used for viability treatments with platinum compounds. A control 106 consisting of genomic RNA or virus suspension without viability marker was included in each 107 assay. Following the viability treatment, the viral RNA was immediately purified as described 108 hereafter.

109 Assessment of PtCl₄ viability RT-qPCR in artificially inoculated and validation in naturally 110 contaminated samples

Platinum (IV) chloride was selected as the most reliable viability marker and tested at final
concentrations of 0.5 to 5.0 mM for viability RT-qPCR optimization in stool, urine,
nasopharyngeal swabs and wastewater samples.

For the initial optimization, stool and urine specimens that had tested negative for SARS-CoV-2 were retrieved from IATA biobank. Faecal material was resuspended 1% w/v in phosphatebuffered saline (PBS), and supernatant recovered by centrifugation at 2000 × g for 5 min. Direct and ten-fold diluted urine, and ten-fold diluted faecal suspension (final 1% w/v faecal dilution) were spiked with either gamma- and/or heat inactivated SARS-CoV-2 to approximately 10^5 gc/L final concentration.

Then, nasopharyngeal swabs from positive COVID-19 patients and naturally contaminated wastewater samples were used to validate the viability PtCl₄ RT-qPCR. Nasopharyngeal swabs (n=9) from COVID-19 positive patients were originally collected at Hospital Clínico Universitario de Valencia (Valencia, Spain) and included in this study once de-identified. To test whether the detection of viral RNA was exclusive for infectious particles, nasopharyngeal swab subsamples were inactivated at 95 °C for 10 min, included in the experiments along with naïve specimen and both assayed by RT-qPCR and viability PtCl₄ RT-qPCR.

SARS-CoV-2 positive wastewater grabbed samples (n=6) were collected in June-October, 2020 127 128 from different wastewater treatments plants involved in a WBE monitoring programme. The 129 samples were originally concentrated by an aluminium precipitation procedure and tested positive for at least two RT-qPCR targets (N1, IP4 or E gene).⁽¹⁴⁾ To exclude additional viral 130 inactivation due to the concentration procedure, wastewater were freshly concentrated by 131 132 Centricon-Plus 70 centrifugal ultrafilters units with a cut-off of 100 kDa (Merk-Millipore, MA, 133 US).⁽¹⁵⁾ Samples were all diluted in PBS as specified. Viability treatment, RNA extraction and 134 SARS-CoV-2 detection were carried out as hereafter detailed.

135 Viral RNA purification and SARS-CoV-2 detection

136 Viral RNA was extracted using Maxwell[®] RSC 16 instrument and Maxwell RSC Pure Food GMO 137 and authentication kit (Promega, Spain) and detected by RT-qPCR targeting N1, N2, E gene, IP2 138 and IP4 regions.⁽¹⁶⁾ Viral RNA from nasopharingeal samples was extracted using a KingFisher™ 139 Flex (Thermo Fisher Scientific) instead. Given the superior sensitivity of N1 RT-qPCR resulting 140 from the initial screening, this target was used for subsequent determinations. Each RT-qPCR 141 assay was performed in duplicate and included nuclease-free water as negative control, and 142 SARS-CoV-2 complete genomic RNA (VR-1986D[™], ATCC, VA, US), E gene plasmid (10006896, 143 2019-nCoV E Positive Control from Charité/Berlin, IDT, Belgium) or N1/N2 plasmid (10006625, 144 2019-nCoV_N_Positive Control from CDC, IDT, Belgium) as positive controls. Ten-fold RNA dilutions were consistently tested to check RT-qPCR inhibition due to viability marker residuesor inhibitory substances in the sample.

147 Statistical analysis

All data were compiled from three independent experiments with at least two technical replicates for each variable. Data are presented as median ± SD. Significant differences in median cycle threshold (Ct) were determined by using either one- or two way(s) ANOVA followed by

151 Dunnett's multiple comparisons test on GraphPad Prism version 8.02 (GraphPad Software, US).

152 Differences in means were considered significant when the p was <0.05.

153 Results

154 Initial assessment of viability markers and RT-qPCR assays

155 With regard to the viability markers tested, platinum compounds were better at preventing PCR 156 amplification of SARS-CoV-2 genomic RNA suspension than monoazide dyes, regardless of the 157 RT-qPCR target (Figure 1). Compared to untreated RNA, significant differences were detected 158 for PtCl₄ and CDDP treated samples in all the five RT-qPCR targets tested. While PtCl₄ completely 159 prevented the RNA amplification for all replicates, it occurred in 5 out of 20 CDDP treated 160 replicates targeting N1, N2 and IP4. Among photoactivatable dyes, 50 μ M PMAxx offered the 161 best performance as it removed the signal in 8 replicates showing statistically significant 162 differences for E gene, IP2 and IP4. An additional assay tested 100 μM PMAxx on SARS-CoV-2 163 genomic RNA without any improvement of the results with respect to 50 μ M PMAxx 164 concentration (data not shown). EMA and PEMAx completely removed RT-qPCR signals in 2 out 165 of 20 replicates. Given these preliminary results, we further assessed PMAxx and PtCl₄ effect on 166 SARS-CoV-2 gamma- (ca. 8.50 x 10⁵ gc/mL corresponding to 140 TCID₅0/mL) and heat inactivated 167 (ca. 1.88×10^5 gc/mL corresponding to 80 TCID₅₀/mL) viral particles by using N1 as the most 168 sensitive RT-qPCR assay among all the compared targets. PMAxx at 50 μ M minimally reduced 169 the PCR signals by 2.82 and 3.17 Cts with respect to the gamma- and heat inactivated controls, 170 while the superior ability of PtCl4 was confirmed for both gamma- and heat inactivated SARS-171 CoV-2 viral particles (Figure 2). A final concentration of 1.0 mM PtCl₄ was needed to consistently prevent the amplification of inactivated viruses by viability RT-qPCR. Thus, we further applied 172 173 the PtCl₄ viability RT-qPCR to high concentrated gamma-inactivated viral suspensions (ca. 8.50 x 174 10⁶ gc/mL). Results showed that 0·5 and 1·0 mM PtCl₄ reduced by 3·4 and 6·8 Cts compared to 175 the control. Although significant statistical differences were detected for all treatments 176 regardless of the concentration of the metal compound, only 2.0 mM PtCl₄ showed to 177 consistently prevent signal amplification (only one positive out of 8 replicates, Ct=39.11).

178 Effect of sample complexity on viability RT-qPCR

179 To determine the effect of sample matrix on viability RT-qPCR, we spiked 10-fold diluted stool 180 suspensions (1% w/v final dilution) and urine specimen (10% v/v final dilution) with 181 approximately 10⁵ gc/mL gamma-inactivated SARS-CoV-2, and applied up to 5.0 mM PtCl₄ as 182 viability marker. Compared to the untreated control, significant differences were observed for 183 1.0 mM PtCl₄ in urine samples or 1.25 mM PtCl₄ in stool suspensions (Figure 3). However, a concentration of 5.0 mM was needed to completely remove the PCR signals in urine, while 2.5 184 185 mM PtCl₄ prevented the amplification of 1 out of 8 replicates in stool. Although the complete 186 inhibition of amplification signals was achieved to a limited extent, a sharp difference above one 187 logarithm of genomic copies (ΔCts≈3·3) was observed in stool and urine samples processed with 188 1.25 and 3.75 mM PtCl₄, respectively.

189 Viability RT-qPCR validation on positive clinical samples and naturally contaminated 190 wastewater

Additional experiments were set up to validate viability PtCl₄ RT-qPCR on nasopharyngeal swabs from COVID-19 positive patients and on naturally contaminated wastewater samples. Initial experiments using undiluted samples achieved unsuccessful results (data not showed), thus both clinical and wastewater samples were ten-fold diluted in PBS buffer. Nine 10-fold diluted nasopharyngeal swabs and the corresponding heat-inactivated (95 °C for 10 min) subsamples were processed by RT-qPCR alone and viability RT-qPCR with either 1.0 or 2.5 mM PtCl₄ (Figure 197 4). Applying 1.0 mM PtCl_4 viability RT-qPCR, consistent amplification signals were observed in

both naïve and heat-treated samples with minimal Ct differences compared to RT-qPCR alone.

199 Increased concentration to 2.5 mM led to a sharper discrimination of PCR signals (Δ Ct=9.24 ±

3.59). Similarly, the complete prevention of RT-qPCR signals occurred in one out of four samples

at 1·0 mM PtCl₄, and in three out of five samples at 2·5 mM (Figure 4). Regardless of the viability
 marker concentration applied, the complete prevention of amplification was observed in
 samples with initial low viral titer (Ct values ≥ 30). Moreover, the 2·5 mM PtCl₄ viability RT-qPCR
 was further validated on six wastewater samples naturally contaminated with SARS-CoV-2. The

results showed that 2.5 mM PtCl₄ completely prevented the amplification in all samples (Figure
5).

207 Discussion

208 Currently, research projects aiming to assess the risk of transmission and exposure to infectious 209 virus either in clinical and environmental settings have been limited by the biosafety level-3 (BSL-210 3) conditions needed to handle infectious SARS-CoV-2. The research effort of this investigation 211 intended to provide a rapid and sensitive analytical method that selectively detects potentially 212 infectious SARS-CoV-2 in a significantly shorter time than the traditional cell-culture based 213 method and that can be used in a wide range of applications, including clinical and 214 environmental COVID-19 monitoring programs as epidemiological response to the pandemic 215 that is causing such a public health emergency.

216 This study evaluated photoactivatable monoazide dyes and metal compounds as viability 217 markers applied prior to nucleic acid extraction to prevent amplification of RNA from non-viable 218 viral particles, thus enabling amplification only of viable/infectious viruses in downstream RT-219 qPCR assay. Selecting platinum chloride as the best performing viability marker, we 220 demonstrated that viability RT-qPCR efficiently discriminated free RNAs and inactivated SARS-221 CoV-2 inoculated in buffer, stool and urine suspensions. Then, we further proved that the 222 method inferred SARS-CoV-2 infectivity better than RT-qPCR alone in both nasopharyngeal 223 swabs from positive COVID-19 patients and in naturally contaminated wastewater samples. In 224 the case of complex matrices, increased PtCl₄ concentration of 2.5 mM and ten-fold sample 225 dilution are recommended because of the presence of suspended solids and inhibitors that 226 hinder the efficacy of the viability treatment.

227 Our investigation initially included five well-established molecular assays since the length of the 228 amplicon and/or the richness of secondary structures of targeted RNA may affect the efficiency of viability treatments.^(17,18) We show that metal compounds performed better than monoazide 229 230 dyes, irrespective of RT-qPCR assays. However, RT-qPCR targeting N1 region is recommended 231 because of its superior sensitiveness. This aspect is of importance because complex matrices 232 needed to be diluted to achieve a more efficient inference of viral infectivity, as demonstrated 233 in spiked stool and urine, in positive swabs and in contaminated wastewater. Similarly, sample 234 dilution was needed to implement a viability RT-qPCR targeting norovirus in sewage.⁽¹⁹⁾ 235 Moreover, N1 assay better fits the testing on samples with expected low viral concentrations 236 (e.g., environmental samples) and/or PCR inhibitors (e.g., concentrated wastewater, stool). As 237 N1 assay has been validated in many laboratories worldwide, this viability method could also be 238 easily and widely implemented.

To the best of our knowledge, this is the first report on a rapid molecular assay independent from viral replication in cell culture developed to test SARS-CoV-2 infectivity. A recent investigation by our group demonstrated the suitability of viability RT-qPCRs to infer the infectivity of porcine epidemic diarrhea coronavirus, member of the genus *Alphacoronavirus* within *Coronaviridae* family.⁽¹³⁾ Interestingly, we were able to demonstrate that PMAxx viability RT-qPCR matched the thermal inactivation pattern obtained by cell culture better than other viability markers, including PtCl₄, and RT-qPCR alone.

Alternative rapid methods to assess the viability of enveloped viruses have been explored with unsuccessful results. These included propidium monoazide and immunomagnetic separation tested on laryngotracheitis virus and ethidium monoazide on avian influenza virus.^(11,12) It is worth to report that we also tested on inactivated SARS-CoV-2 suspensions a porcine gastric
 mucine *in situ* capture RT-qPCR, a method that was originally implemented in our laboratory for
 human enteric viruses.⁽²⁰⁾ Although proper SARS-CoV-2 infectious controls could not be included,
 those experiments resulted in inconclusive outcomes (data not shown).

Our viability RT-qPCR results of nasopharyngeal swabs from positive COVID-19 patients indicate the potential infectivity of the samples, while naturally contaminated wastewater are unlikely to contain infectious viral particles. These later findings reflect the viral replication in cell culture from RNA positive stool and respiratory samples as well as the unsuccessful attempts to isolate and cultivate SARS-CoV-2 from wastewater samples.⁽²¹⁻²³⁾

258 Our findings are clinically relevant as RT-qPCR has become the primary method to diagnose 259 COVID-19. However, as it detects RNA, its ability to determine the infectivity of patients is 260 limited.⁽⁵⁻⁸⁾ In addition, the immune system can neutralise SARS-CoV-2 preventing subsequent 261 infection but not eliminating nucleic acid, which degrades slowly over time. This has been 262 confirmed in cohort studies that concluded that seroconversion does not necessarily lead to the 263 elimination of viral RNA, with cases being RT-PCR positive up to > 63 days after symptom onset despite having neutralizing antibodies.^(24–26) Furthermore, some reports correlated the 264 265 infectiousness of upper respiratory tract samples with RT-qPCR Ct values in COVID-19 cases. 266 Analysing a large dataset (n=324), Singanayagam and colleagues demonstrated that the probability of viral recovery from samples with 27.5 < Ct < 30 was ≈66%, decreasing to ≈ 28% for 267 30 < Ct < 35, and to 8.3% for Ct > 35.⁽²³⁾ Similarly, Bullard observed SARS-CoV-2 cell infectivity 268 only for respiratory specimens sampled < 8 days symptom onset with Ct < 24.⁽²⁷⁾ However, viral 269 270 replication was also obtained from samples with elevated Ct values of 36-39.^(7,28) 271 Notwithstanding, the correlation between RNA and virus isolation remains unclear.

Unfortunately, we had no access to clinical samples with higher Ct values which are likely to contain non-infectious particles to contrast such hypothesis by the proposed viability RT-qPCR. In addition, the ratio between viral shedding and infectivity has been reported to vary along the course of the infection.^(4,6,22) This information regarding epidemiological characteristics, symptom history and relevant sampling details included in medical records could have explained at least in part the different performances of viability RT-qPCR among clinical samples, however it could not be retrieved as de-identified specimens were analysed in this study.

279 Despite the viability treatment, we detected residual signals in heat inactivated nasopharyngeal 280 swabs. This could be attributed to the viral envelop and nucleoproteins that limit the access 281 and/or the binding of viability markers to SARS-CoV-2 RNA, as hypothesised for avian influenza virus and bacteriophage T4. ^(12,29) The enveloped structure of coronaviruses may also explain the 282 increased concentration of viability markers needed for SARS-CoV-2 and PEDV compared to 283 284 human enteric viruses.^(13,19,30) This cumbersome finding obtained by the proposed viability 285 procedure suggests that the overestimation of the infectivity of a given sample may occur which, 286 although warranting a careful interpretation, represents a conservative prediction. With regards 287 to wastewater samples that tested positive for SARS-CoV-2 RNA, they most probably contained 288 detergents and chemicals that are detrimental to viral infectivity further supporting the efficacy 289 of the viability RT-qPCR in discriminating potentially infectious and inactivated viral particles.⁽³¹⁾ 290 The ultimate confirmation on the infectivity of the samples by cell culture, although 291 recommendable, could not be provided. Detection of SARS-CoV-2 by either culture and viability 292 RT-qPCR is valuable as a proxy for infectiousness; however, as the human infectious dose 293 remains unknown, the significance of low titres of infectious virus for human-to-human 294 transmission remains uncertain. Above all, as some individuals reportedly remain PCR positive 295 weeks after SARS-CoV-2 infection recovery, knowing whether viral RNA in these persistent 296 carriers is contagious provides key insights for quarantine policy, to safely discontinue self-297 isolation and contact tracing as essential public health measures to definitively prevent 298 transmission.^(6,26,32) Besides some limitations, the proposed viability RT-qPCR effectively reduced 299 the amplification signals of non-infectious and free RNA of SARS-CoV-2 in complex matrices 300 finally providing a better estimation of the infectiousness of samples. Thus, mathematical 301 models derived from laboratory scale experiments comparing viability RT-qPCR and viral 302 replication could correlate viral load and infectivity, finally providing relevant tools of interest 303 based on rapid molecular assay for prevention strategies and risk assessment.

304 Conclusions

305 In conclusion, the use of pre-treatments to prevent RT-qPCR amplification of RNA from non-306 infectious SARS-CoV-2 using platinum chloride as a viability marker of infectivity was 307 implemented in stool and urine samples and successfully validated in naturally contaminated 308 wastewater samples, supporting the idea that SARS-CoV-2 present in sewage is not infectious. 309 Residual amplification signals in nasopharyngeal swabs exposed to heat-inactivation 310 overestimated the amount of viable virus, still providing a conservative interpretation of the 311 infectiousness of the sample. Our study proposes a rapid analytical tool based on viability RT-312 qPCR to infer SARS-CoV-2 infectivity with potential application in risk assessment, and 313 prevention and control in public health programmes.

314 Contributors

GS, AA and WR conceived the study with input from AP-C, IF, SML and EC-F. EC-F, IF, AD-R, and IG-G led data acquisition. DN provided the nasopharyngeal swabs from COVID-19 positive patients. GS, EC-F, and WR led data analysis, interpretation, and visualisation. EC-F and WR wrote the draft report, and all other authors revised the report critically for important intellectual content. All authors critically reviewed and approved the final version of the manuscript.

321 **Declaration of interests**

322 All authors declare no competing interests.

323 Acknowledgements

The study was supported by CSIC (202070E101), Generalitat Valenciana (Covid_19-SCI), MICINN co-founded by AEI/FEDER, UE (AGL2017-82909), and MICINN/AEI (PID2019-105509RJ-I00). EC-F is recipient of a predoctoral contract from the MICINN, Call 2018.

327 We thank Agustin Garrido Fernández and Andrea Lopez de Mota at IATA-CSIC for providing

- 328 support in sample processing. We acknowledge Global Omnium S.L., NILSA, Aguas de Malaga,
- 329 ESAMUR and FACSA for coordinating and managing wastewater sampling.

330

331	References		
332	1.	Meselson M. Droplets and aerosols in the transmission of SARS-CoV-2. <i>N Engl J Med</i> 2020;	
227	r	Gue M. Tae W. Elavell PA. Zhu S. Detential intestinal infection and faecal eral	
225 225	Ζ.	transmission of SARS CoV 2. Nat Ray Castroontarol Honatol 2021	
335	2	Liansmission of SARS-COV-2. Nat Rev Gastroenterol Hepatol 2021.	
330	3.	Bivins A, North D, Anmad A, Anmed W, Aim E, Been F, et al. Wastewater-Based	
337		Epidemiology: Global Collaborative to Maximize Contributions in the Fight against COVID-	
338		19. Environ Sci Technol 2020; 13:7754–7.	
339	4.	Owusu D, Pomeroy MA, Lewis NM, Wadhwa A, Yousar AR, Whitaker B, et al. Persistent	
340		SARS-COV-2 RNA Shedding without Evidence of Infectiousness: A Conort Study of	
341	-	Individuals with COVID-19. J Infect Dis 2021; Jiab107.	
342	5. c	Alkinson B, Petersen E. SARS-COV-2 shedding and infectivity. Lancet 2020; 395 :1339–40.	
343	6.	widders A, Broom A, Broom J. SARS-COV-2: The viral shedding vs infectivity dilemma.	
344	-	Inject Dis Heal 2020; 25 :210–5.	
345	7.	Romero-Gomez MP, Gomez-Sebastian S, Cendejas-Bueno E, Montero-Vega MD,	
346		Wingorance J, Garcia-Rodriguez J. Ct value is not enough to discriminate patients	
347	~	narbouring infective virus. J infect 2021; 20 :30720-9.	
348	8.	Krupp K, Madnivanan P, Perez-Velez CM. Should qualitative RT-PCR be used to determine	
349	~	release from isolation of COVID-19 patients? J Infect 2020; 3 :452–82.	
350	9.	Ogando NS, Dalebout IJ, Zevennoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, et	
351		al. SARS-coronavirus-2 replication in vero E6 cells: Replication kinetics, rapid adaptation	
352	4.0	and cytopathology. J Gen Virol 2020; 9 :925–940.	
353	10.	Leifeis M, Dan C, Sozzi E, Shoults DC, Wuertz S, Mongkoisuk S, et al. Capsid integrity	
354		quantitative PCR to determine virus infectivity in environmental and food applications – A	
355	4.4	systematic review. <i>Water Res X</i> 2020; 11 :100080.	
350	11.	Bindari YR, Walkden-Brown SW, Gerber PF. Methods to prevent PCR amplification of DNA	
357		trom non-viable virus were not successful for infectious laryngotracheitis virus. PLoS UNE	
358	10	2020; 5 :e0232571.	
359	12.	Graiver DA, Saunders SE, Topliff CL, Kelling CL, Bartelt-Hunt SL. Ethidium monoazide does	
360		not inhibit RT-PCR amplification of nonviable avian inhuenza RNA. J virol iviethous 2010;	
301	10	104:51-4.	
362	13.	Puente H, Randazzo W, Faico I, Carvajal A, Sanchez G. Rapid Selective Detection of	
303		Potentially Infectious Porcine Epidemic Diarmea Coronavirus Exposed to Heat Treatments	
364	1.4	Using Viability RI-qPCR. Front Microbiol 2020; 11:1911.	
305	14.	Randazzo W, Truchado P, Cuevas-Ferrando E, Simon P, Allende A, Sanchez G. SARS-CoV-2	
366 367		2020; 181 :115942.	
368	15.	Medema G, Heijnen L, Elsinga G, Italiaander R, Brouwer A. Presence of SARS-Coronavirus-	
369		2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of	
370		the Epidemic in The Netherlands. Environ Sci Technol Lett 2020; acs.estlett.0c00357.	
371	16.	Pérez-Cataluña A, Cuevas-Ferrando E, Randazzo W, Falcó I, Allende A, Sánchez G.	
372		Comparing analytical methods to detect SARS-CoV-2 in wastewater. Sci Total Environ	
373		2021; 758 :143870.	
374	17.	Contreras PJ, Urrutia H, Sossa K, Nocker A. Effect of PCR amplicon length on suppressing	
375		signals from membrane-compromised cells by propidium monoazide treatment. J	
376		Microbiol Methods 2011; 1:89–95.	
377	18.	Soejima T, Schlitt-Dittrich F, Yoshida S-I. Polymerase chain reaction amplification length-	
378		dependent ethidium monoazide suppression power for heat-killed cells of	
379		Enterobacteriaceae. Anal Biochem 2011; 1:37–43.	
380	19.	Randazzo W, López-Gálvez F, Allende A, Aznar R, Sánchez G. Evaluation of viability PCR	
381		performance for assessing norovirus infectivity in fresh-cut vegetables and irrigation	
382		water. Int J Food Microbiol 2016; 229:1–6.	

- Falcó I, Randazzo W, Rodríguez-Díaz J, Gozalbo-Rovira R, Luque D, Aznar R, et al. Antiviral
 activity of aged green tea extract in model food systems and under gastric conditions. *Int J Food Microbiol* 2019; **292**:101–6.
- Rimoldi SG, Stefani F, Gigantiello A, Polesello S, Comandatore F, Mileto D, et al. Presence
 and infectivity of SARS-CoV-2 virus in wastewaters and rivers. *Sci Total Environ* 2020;
 744:140911.
- Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
 assessment of hospitalized patients with COVID-2019. *Nature* 2020; **7809**:465–9.
- 391 23. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of
 392 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,
 393 England, January to May 2020. *Euro Surveill* 2020; **32**:2001483.
- 394 24. Molina LP, Chow S-K, Nickel A, Love JE. Prolonged detection of Severe Acute Respiratory
 395 Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an obstetric patient with antibody
 396 seroconversion. *Obstet Gynecol* 2020; **4**:838–41.
- Liu W-D, Chang S-Y, Wang J-T, Tsai M-J, Hung C-C, Hsu C-L, et al. Prolonged virus shedding
 even after seroconversion in a patient with COVID-19. *J Infect* 2020; **2**:318–56.
- Vibholm LK, Nielsen SSF, Pahus MH, Frattari GS, Olesen R, Andersen R, et al. SARS-CoV-2
 persistence is associated with antigen-specific CD8 T-cell responses. *EBioMedicine* 2021;
 64:103230.
- 402 27. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious
 403 SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* 2020; ciaa638.
- 28. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019
 (COVID-19) in the United States. *Nat Med* 2020; 6:861–8.
- Fittipaldi M, Rodriguez NJP, Codony F, Adrados B, Peñuela GA, Morató J. Discrimination of
 infectious bacteriophage T4 virus by propidium monoazide real-time PCR. *J Virol Methods*2010; **168**:228–32.
- 30. Randazzo W, Vasquez-García A, Aznar R, Sánchez G. Viability RT-qPCR to distinguish
 between HEV and HAV with intact and altered capsids. *Front Microbiol* 2018; **9**:1973.
- 411 31. Khokhar M, Roy D, Purohit P, Goyal M, Setia P. Viricidal treatments for prevention of
 412 coronavirus infection. *Pathog Glob Health* 2020; **7**:349–59.
- 413 32. Esteve C, Catherine FX, Chavanet P, Blot M, Piroth L. How should a positive PCR test result 414 for COVID-19 in an asymptomatic individual be interpreted and managed? *Med Mal Infect*
- 415 2020; **8**:633–638.

Figure 1. Performance of monoazide photoactivatable dyes and platinum compounds on SARS-CoV-2 genomic RNA assessed by targeting five different RNA regions. Dashed grey line represents RT-qPCR theoretical limit of detection for N1, N2 and gen E; dotted grey line represents RT-qPCR theoretical limit of detection for IP2 and IP4. Asterisks indicate significant difference from untreated control for each molecular target: ns, not significant; *p<0.01; **p<0.001; ***p<0.0001; ns, not significant.



Figure 2. Assessment of viability markers on inactivated SARS-CoV-2 viral particles suspended in PBS buffer at different concentrations. RT-qPCR assays targeted N1 region. A) Comparison of PMAxx and platinum chloride (PtCl₄) viability RT-qPCRs on low (ca. 10^3 gc/mL) gamma- and heat inactivated SARS-CoV-2 viral particles. B) Viability RT-qPCR optimization using increasing concentration of PtCl₄ on high concentrations of gamma-inactivated SARS-CoV-2 viral particles (ca. 10^5 gc/mL). Dashed grey lines represent RT-qPCR theoretical limit of detection. Asterisks indicate significant difference from untreated control: *p<0.01; **p<0.001; ***p<0.0001.



429Figure 3. Platinum chloride (PtCl₄) viability RT-qPCR on ten-fold diluted faecal suspensions (1%430w/v final dilution) (brown dots) and urine specimens (10% v/v final dilution) (green dots) spiked431with approximately 10^5 gc/mL gamma-inactivated SARS-CoV-2. Dashed grey line represents RT-432qPCR theoretical limit of detection. Asterisks indicate significant difference from untreated433control: *p<0.01; **p<0.0001; ns, not significant.</td>



Figure 4. Validation of viability RT-qPCR with either 1mM or 2·5 mM PtCl₄ on ten-fold diluted
nasopharyngeal swabs from COVID-19 positive patients. Plotted dots represents the median
cycle threshold value (Ct) of naïve and heat-inactivated (95 °C for 10 min) subsamples assayed
by RT-qPCR alone and viability RT-qPCR both targeting N1. Dashed grey line represents RT-qPCR
theoretical limit of detection.



439 Figure 5. Validation of 2.5 mM PtCl₄ viability RT-qPCR on ten-fold diluted naturally contaminated wastewater samples. Dashed grey line represents RT-qPCR theoretical limit of detection. 440



441 Research in context

442 Evidence before this study

443 Previous works have established RT-gPCR methods for the efficient detection of severe acute 444 respiratory syndrome coronavirus 2 in stool, urine and respiratory samples, with the latter being 445 the most commonly used specimens in tracing COVID-19 cases. Similarly, wastewater-based 446 epidemiology has been globally implemented to monitor the community spread of the virus. 447 However, SARS-CoV-2 RNA load in clinical and environmental samples is not indicative of 448 infectiousness. The distinction between viral shedding and infectivity is important for the 449 development of prevention policy and quarantine guidelines as well as for the assessment of 450 the risk of contamination in environmental settings. Some reports correlated RT-PCR Ct value 451 and culture positivity and there is scientific evidence that persistent PCR positive individuals are 452 not transmitting at the post-symptomatic stage of infection. However, testing viral replication is 453 not feasible for large scale clinical screening or for environmental surveillance. In addition, the 454 biosafety level 3 laboratory requirements needed to handle SARS-CoV-2 infectious materials and 455 the turnaround time for culture results has also limited investigation on related topics. Previous 456 works have established rapid viability assays based on RT-qPCR pre-treatments to infer the 457 potential infectivity of enteric viruses, including norovirus, hepatitis A and E viruses in 458 environmental and food samples. Unsuccessful attempts were reported for influenza virus and 459 infectious laryngotracheitis virus, while a viability RT-qPCR for the selective detection of 460 infectious and heat-inactivated porcine epidemic diarrhea coronavirus, as an enveloped viral 461 model, was recently proposed. However, the sensitivity and reliability of this method remains 462 to be shown for SARS-CoV-2.

463 Added value of this study

We show that SARS-CoV-2 RNA amplification of non-infectious samples can be reproducibly prevented by processing clinical and wastewater samples by a platinum chloride viability RTqPCR technique. To the best of our knowledge this is the first report on this subject that also provides the following distinguishing features: (i) the procedure was optimized using standard materials which include SARS-CoV-2 genomic RNA, gamma- and heat inactivated viral particles; (ii) the preliminary findings were validated in nasopharyngeal swabs from COVID-19 positive patients and in wastewater samples naturally contaminated with SARS-CoV-2 RNA.

471 Overall, this study allows to selectively detect SARS-CoV-2 RNA belonging to potentially
472 infectious viral particles in complex matrices of interest for epidemiological surveillance and
473 pandemic control.

474 Implications of all the available evidence

Extensive lockdown measures are currently allowing to partially mitigate the spread of SARS-CoV-2. As such, it is of extreme importance to set up feasible and reliable epidemiological surveillance strategies that include clinical and environmental monitoring programs. Information on the infectivity of such samples is the keystone to better define the transmission route(s) and the risk of exposure. Further developments of predictive models based on such a viability approach may have a broad range of applications: including risk assessment, food safety and public health policy.